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Abstract
Severe disease is associated with serial infection with DENV of different 
serotypes. Thus, primary DENV infections normally cause asymptomatic infec-
tions, and secondary heterotypic infections with a new DENV serotype potentially 
increase the risks of developing severe disease. Despite many proposed hypotheses 
trying to explain it, the exact immunological mechanism leading to severe dengue 
disease is unknown. In turn, severe manifestations are believed to be a consequence 
of the combinations of many immunopathogenic mechanisms involving viral 
and host factors leading to increased pathogenesis and disease. Of these mecha-
nisms, the adaptive immune response has been proposed to play a critical role 
in the development of severe dengue manifestations. This includes the effect of 
non-neutralizing but enhancing antibodies produced during primary infections, 
which results in enhanced-DENV infection of Fc-γ-receptor-expressing cells (e.g. 
monocytes and macrophages) during DENV heterotypic exposure in a phenomenon 
called antibody-dependent enhancement (ADE); the increased activation of memory 
T cells during secondary infections, which has low affinity for the current infecting 
serotype and high affinity for a past infection with a different serotype known as 
the original antigenic sin; the unbalanced production of pro-inflammatory cytokines 
that have a direct effect on vascular endothelial cells resulting in plasma leak in a 
phenomenon known as cytokine storm; and the excessive activation of the comple-
ment system that causes exacerbated inflammatory responses, increasing disease 
severity. In addition to the adaptive immune responses, a secreted viral factor known 
as the nonstructural protein 1 (NS1) has been recently proposed as the missing corner 
piece of the DENV pathogenesis influencing disease. This Part II of the chapter 
will discuss the interplay between the distinct host adaptive immune responses and 
viral factors that together contribute to the development of DENV pathogenesis and 
severe disease.
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1.  Dengue immunopathogenesis and severe disease: host and viral 
factors
As discussed in Part I of this chapter, severe dengue is mainly characterized 
by the altered endothelial function in blood vessels and the disruption of the 
coagulation cascade that results in hypotension, shock, and severe hemorrhage 
manifestations [1, 2]. As the epidemiology of dengue indicates that appearance of 
severe manifestations occurs when the peak of viremia has passed, the key biologi-
cal mechanisms leading to the pathogenesis of clinical complications during DENV 
infection, are believed to involve the activity of short-lived biological mediators 
closely linked to host innate and adaptive immune responses [3–6].
This Part II of the dengue immunopathogenesis section will address the mul-
tifactorial immunopathogenic process of DENV infection from the perspective of 
the pre-existing serotype cross-reactive antibodies, the hyperactivation of DENV-
infected immune cells (e.g. monocytes, mast cells) leading to increased cytokine 
production, the role of T cell responses, the activation of complement pathways, 
and the new pathogenic roles of the secreted NS1 of DENV that may act together to 
occasionally cause severe dengue manifestations followed by shock and potentially 
death [1, 6–21].
1.1 Antibody response to DENV infection
The DENV complex refers to a group of four evolutionarily distinct, but antigeni-
cally and genetically related DENV serotypes (DENV-1 to DENV-4) [22]. During 
dengue disease, the humoral immune response is vital for controlling DENV virus 
infection and for the development of acquired immunity [10]. Neutralizing anti-
bodies against the four serotypes are critical components of the protective immune 
response [23]. In this sense, during primary DENV infection, it is expected that a 
neutralizing type-specific antibody response should provide long-term protection 
against the primary DENV infecting serotype, but only transient protection against 
other DENV serotypes (cross-reactive antibodies) (See Figure 1 Part I). Infection 
with a primary serotype is thought to induce lifelong immunity that protects against 
re-infection with the same serotype (homotypic) [7, 23]. However, homotypic 
DENV infections have been found in symptomatic dengue cases in a community-
based prospective cohort study suggesting that recurrent DENV infections, par-
ticularly in endemic areas can occurs in patients over time [24]. After subsequent 
infection with a different serotype (secondary infection), the neutralizing antibody 
response becomes broadly neutralizing and is thought to reduce the incidence of 
severe disease [25] (See Figure 1C, Part I). In fact, individuals with higher cross-
reactive neutralizing antibody titers originated from pre-infection correlates with 
reduced likelihood of symptomatic secondary infection [23]. However, numerous 
studies worldwide involving human infections during dengue epidemics (e.g. 
hospitalized cases) or multiple epidemiological studies from prospective cohorts 
strongly support the heterotypic secondary DENV infection, defined as two or more 
sequential infections by different serotypes, as the epidemiologic greatest risk factor 
for developing severe dengue disease [17, 26–29].
Antibody responses during DENV infection are mainly directed against the 
envelope protein (E), the major structural protein of the virion, and the dominant 
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antigenic target for DENV neutralizing antibodies during natural infection, thus 
the focus of vaccine candidates design [30–32]. Antibodies specific for DENV 
proteins can mediate a wide range of functions in vitro [10]. They can neutralize 
DENV infection by direct hindering of virus-receptor interactions, blocking viral 
fusion with the endosomal membrane within host cells, viral clearance in a Fc- 
receptor dependent manner, lysis of virus infected cells via complement activation, 
and antibody dependent cell cytotoxicity (ADCC) of infected cells [33] (Figure 1). 
The E glycoprotein is composed of three structural domains (DI, DII, DIII), and 
the most extensive characterization of B cell epitopes has been conducted against 
them [34]. Neutralizing antibodies against the E protein of DENV include antibod-
ies to nearly all the epitopes [35]. However, during the natural course of infection, 
the serological response to the E glycoprotein is highly serotype cross-reactive and 
predominantly targets epitopes containing highly conserved residues, for instance, 
the fusion loop of the domain II [31]. In addition, high-avidity and highly neutraliz-
ing antibodies against DENV, bind to domain III (DIII) of the E glycoprotein, which 
is implicated in DENV binding to its cognate receptor [36, 37]. These antibodies 
appear to be most effective at providing protection from infection and/or disease 
[38–40]. However, with an ~60% amino acid divergence between the E glycopro-
teins of all four DENV serotypes, immunity to one serotype usually does not confer 
long-lasting cross-protective immunity to the other serotypes [41]. A mature DENV 
particle contains 180 copies of the E protein covering the surface of the virion 
in either dimeric or trimeric (pre-fusion) conformations [42]. Neutralization is 
estimated to require a minimum occupancy of ~30 epitope sites per virion [34]. 
This may be attributed to the dense arrangement of E glycoproteins on the virion 
surface which has shown to be important for antigenicity, as many potently neutral-
izing human antibodies against flaviviruses that target either hidden cryptic or 
 quaternary epitopes extent through multiple E proteins [43–47].
On the other hand, the adaptive immune response during DENV infection can 
also generate antibodies against pre-M proteins which are highly serotype cross-
reactive [48]. Despite this high cross-reactivity, anti-pre-M antibodies rarely neu-
tralize DENV infection even at high concentrations [48]. The pre-M protein forms 
a heterodimer with the E protein, and it gets cleaved by host cell-expressed furin 
during the final stage of virion maturation before egress [42]. The cleavage of pre-M 
is required for the activation of flavivirus infectivity, including DENV [49]. In the 
mature virion, the remaining M protein fragment is completely hidden by the E pro-
tein dimers which makes it inaccessible to antibody binding [34]. Therefore, matura-
tion state of the virion matters and may influence the interaction between immature 
virus particles and anti-pre-M antibodies leading to neutralization or enhancement of 
the infection (Figure 1). The potential role of anti-E or pre-M antibodies in increas-
ing DENV infection and pathogenesis will be further discussed later in this chapter.
Antibody responses in DENV infection can be also directed against several non-
structural proteins such as NS1, NS3, and NS5 as found in sera collected from DENV 
infected patients [50, 51]. These antibody responses have been mainly detected 
during secondary cases which open the possibility of implementing it in early 
diagnostic assays of DENV infection [51, 52]. NS3 (viral helicase/protease) and NS5 
(virus RNA dependent polymerase) localize exclusively within virus-infected cells, 
but cell lysis owing to viral cytopathic effect or immune cell-mediated lysis may 
make these proteins accessible for binding to B cell receptors, inducing an antibody 
response [40, 52]. In this same line of interest, T cells may play an important role in 
the immune response against DENV nonstructural proteins. This topic will be later 
discussed in this chapter. On the other hand, the NS1 protein is the only flavivirus 
glycoprotein secreted by infected cells [53]. NS1 forms a multimeric structures 
either expressed on the surface of infected cells (dimer) or released as a soluble 
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Figure 1. 
The supercomplex interplay of the immunopathogenic mechanisms triggered by systemic DENV infection leading 
to disease. The DENV complex is composed by four serotypes [1–4], and a primary infection with any of these 
serotypes triggers an adaptive immune response that results in the generation of neutralizing antibodies mainly 
directed against the infecting serotype, for instance, DENV-1 (here in yellow) [1, 2](see also Figure 1c, Part I). 
When the host is re-exposed to the same DENV serotype as the one from the primary infection (homotypic 
infection), the neutralizing antibodies generated during the first encounter, prevent APCs to be infected [2]. 
However, during a sequential DENV infection with a different serotype, here DENV-2 (in blue) [3], the 
pre-existing antibody response (1st DENV infection) do not neutralize but increases the infection of APCs via a 
mechanism called antibody-dependent-enhancement (ADE). This ADE phenomenon relies on the cell surface 
expression of Fcγ-receptors (FcγRs) including FcγRI (CD64) and FcγRII (CD32) mainly found in monocytes/
macrophages and dendritic cells [1, 3], also Fc εR found in mast cells resident of the skin (see also Figure 2, Part I). 
Importantly, ADE can be also modulated by the structural heterogeneity of the DENV particles (maturation 
state) [4]. During the DENV replication cycle, right before virus exocytosis of the infected cell, the newly assembled 
virus particles suffer a final processing step known as the ‘maturation state’ of the virion, in which the pre-M 
protein is cleaved by the cellular protease, furin. Inefficient furin activity leads to the release of viral particles 
containing a wide variety of pre-M/E protein complex known as partially mature virions [4]. Although immature 
and partially mature DENV viral particles are unable to infect cells via its cognate receptor, they can use the ADE 
mechanisms as a way to infect FcR-bearing cells which results in increased viral production (high virus yield) and 
increased secretion of cytokines and chemokines and other soluble components with vasoactive and pro-
inflammatory activities in a process known as the ‘cytokine storm’. [5] The term “cytokine storm” is referred to the 
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exacerbated and unbalanced production of cytokines and chemokines which exert many effector functions 
including antiviral response and inflammation. Many of these components pose some vasoactive activities which 
alter the homeostasis of mostly all biological barriers including the microvascular endothelium, leading to a 
phenomenon called vascular leak (hereafter, ‘leak’), a consequence of the increased endothelial cell (EC) 
permeability, and a hallmark of severe dengue disease [6]. The homeostasis of the endothelial barrier is mainly 
maintained by two structures: a) the endothelial glycocalyx layer (EGL), a network of membrane-bound 
glycosaminoglycans (e.g heparan sulfate [HS], hyaluronic acid [HA], chondroitin sulfate [CS]) and proteoglycans 
(e.g syndecan-1, perlecan, glypicans), covering the endothelium luminally and playing critical roles in vascular 
physiology and pathology, including mechanotransduction, hemostasis, signaling, and blood cell-vessel wall 
interactions; and b) the intercellular junction complex (IJC), mainly composed of the tight (e.g. ZO-1, occluding, 
claudins) and adherens (e.g. VE-cadherin, beta-catenin) junction proteins that maintain the cell-to-cell contacts 
to control fluids and small molecules exchange between the luminal side (bloodstream) and the abluminal side 
(tissues compartment) of blood vessels. The disruption of any of these two main components under pathological 
conditions leads to increased inflammatory responses with pathogenic consequences involving barrier dysfunction 
and vascular disorders that result in excessive extravasation of fluids and proteins into the tissues, hypotension, 
shock, and sometimes, death. In addition to modulating the endothelial barrier function, cytokine and chemokines 
secreted by DENV infected cells pose important effector functions that promote the recruitment and activation of 
other immune cells such as NK cells with the ability to induce apoptosis of susceptible target cells (e.g. DENV 
infected cells) via NK cell-mediated cytotoxicity, and antibody (Ab)-dependent NK cell-mediated cytotoxicity 
(ADCC) [7]. Activation of NK cells also lead to the secretion of an array of immunoregulatory cytokines which 
conditioned a bidirectional crosstalk between NK cells and other immune cells such as dendritic cells (DC), 
macrophages, mast cells, and T cells. The release of cytotoxic granules and cytokines by NK cells may also 
contribute to a cytokine storm, and the tissue damage associated with infection clearance may exacerbate the 
pro-inflammatory environment. On the other hand, during DENV infection of immunes cells, viral clearance of 
DENV results from a coordinated action of multiple cell types and mechanisms including innate immune responses 
such as the production of type I and type II interferons, cell killing by cytotoxic lymphocytes and production of 
neutralizing antibodies by B cells [7, 8, 9]. Intracellular expression of newly synthesized DENV proteins (e.g. NS3, 
NS1, NS5 proteins) enter the MHC class I and II presentation pathways in which viral peptide epitopes are 
presented on the cell surface either through MHC class II molecules for CD4+ T cells, and MHC class I molecules 
for CD8+ T cells, which principally lyse infected cells but also produce cytokines with effector functions on the 
endothelial biology. Like with the antibody response, after primary DENV infection, T cell responses are mainly 
characterized by higher homotypic than heterotypic responses [8, 10]. However, during DENV secondary 
infections, this pattern breaks down as B and T cells induced by the prior exposure to a different DENV serotype 
rapidly turn into highly serotype cross-reactive responses mainly directed against the previously encountered DENV 
serotype [11]. This phenomenon results in the consistent preferential expansion of pre-existing cross-reactive 
heterologous memory T cells with higher avidity for the previous DENV serotype and weak-affinity for the new 
infecting DENV, that may lead to an inefficient in clearing DENV infection, while producing excessive cytokines, 
leading to the onset of immune pathology such as vascular leak which results in severe disease. This alteration in 
the T cell immune responses, skewed by the ‘memory’ of the previous infection, is referred to as ‘original antigenic 
sin’ [12]. In addition to these host factors, the non-structural protein 1 (NS1) of DENV is a multifaceted viral 
factor that has been also demonstrated to play many roles in DENV pathogenesis. In DENV infected cells, NS1 can 
be found intracellularly expressed as a monomer in the ER where it forms dimers that play critical roles in the 
viral replication cycle, particularly the assembly of new viral particles [13]. Secreted NS1 protein from DENV 
infected cells is a hexameric protein with a barrel-like shape that contains a hydrophobic lipid core (cholesterol 
and triglycerides), and three domains known as the “wing domain”(here in yellow), the β-ladder domain (in 
blue), and the β-roll domain (in red) ([14], see also Figure 1B). Plasma circulating levels of soluble NS1 (sNS1) 
have been described to correlate with the appearance of severe disease manifestations such as dengue hemorrhagic 
fever (DHF) in DENV-infected patients [15]. sNS1 from DENV has been shown to act as a potential pathogen 
associated-molecular pattern (PAMP) that on immune cells and platelets interacts with Toll-like receptor 4 
(TLR4), a pattern-recognition-receptor (PPR) [16] resulting in the production of pro-inflammatory cytokines 
from human PBMCs and monocytes [17] and the activation of human platelets which results in their aggregation 
and increase adherent onto the ECs lining the blood vessels, which hampers the homeostasis of the EC-barrier and 
the microvasculature [18]. Due to its ability to trigger the production of cytokines via TLR4, the term ‘viral toxin’ 
is now used to describe this pathogenic function of sNS1 during systemic DENV infection [14]. Furthermore, sNS1 
can activate and block the antiviral activity of the complement pathway, an important component of the innate 
immune response against many human pathogen infections [19]. NS1 can either lead to pathogenesis by increasing 
the deposition of active complement components on the surface of ECs and human tissues [20], or by directly 
interacting with the component itself blocking its function or getting rid of some of the critical components 
involved in complement activation cascade [19]. An additional route for NS1 to cause virus pathogenesis or 
protection is related to the adaptive immune response generated against the secreted NS1 protein during DENV 
infection [21]. First, NS1-induced autoantibodies (anti-NS1 antibodies that recognize antigens on the host 
components) increase the activation of ECs causing barrier dysfunction by increasing the production of 
proinflammatory cytokines and the action of the complement pathway or binds to autoantigens encoded in 
proteins of the clotting cascade such as plasminogen, thrombin, and fibrinogen inducing coagulation disorders that 
along with the thrombocytopenia leads to bleeding manifestations [22, 23]. Second, anti-NS1 antibodies have been 
reported to prevent the direct interaction of sNS1 with the surface of ECs which blocks the NS1-induced activation 
of endothelial-intrinsic pathways leading to the disruption of the EGL and the remodeling the cell-to-cell contacts 
which disrupts the integrity of the intercellular junction complex formed by tight and adherens junction proteins 
(TJ/AJ) [24–26]. Overall, this summary figure represents the complex crosstalk between distinct host and viral 
factors that together trigger a diverse cascade of effector functions leading to protection or pathogenesis, the latter 
sometimes associated to the development of life-threatening disease manifestations that can result in death.
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hexameric during DENV infection in vitro and in vivo (See Figure 1B, Part I)  
[12, 54–56]. Specific antibodies for NS1 proteins have been also found circulating 
in DENV infected patients, particularly in secondary cases and are highly serotype 
cross-reactive [57–59].
In vivo experiments using mouse models for DENV infection, the adoptive 
transfer of immune serum or monoclonal antibodies specific for pre-M, E or NS1 
proteins prevented mortality from lethal challenge with DENV [9, 38, 60–63]. 
Similarly, passive transfer of anti-E antibodies can protect against infection with 
DENV in nonhuman primate models [64, 65]. Dengue virus-specific antibodies of 
the appropriate subclasses can also bind to complement proteins and promote their 
activation. Fixation of complement to virions by antibodies specific for the pre-M 
and/or E proteins can inhibit viral infection [66]. NS1-specific antibodies mediate 
complement-dependent lysis of infected cells; however, this may not fully explain 
their protective effects in vivo [67]. Additionally, NS1-specific antibodies may also 
contribute to antibody-dependent cellular cytotoxicity [67, 68]. Recently, the role of 
the antibody immune response against the soluble DENV NS1 has become more rel-
evant in the development of future dengue vaccines [9, 62, 69] as NS1 was described 
to play a key role in the development of DENV pathogenesis. Further evidences 
from a candidate dengue vaccine has demonstrated the functionality of anti-NS1-
specific IgG responses against NS1 pathogenesis in vitro [70]. The phenomenon of 
NS1 being directly involved in modulating DENV pathogenesis will be discussed in 
more detail in a different section of this chapter.
1.2  Antibody-dependent enhancement of DENV infection and the cytokine 
storm
DENV has four distinct serotypes, and infection with one serotype results in the 
development of homotypic immunity which has been suggested to confer a durable 
and possible life-long protection against the infecting DENV serotype, but only 
short-term cross-reactive protection against other serotypes (heterotypic immu-
nity) [13]. This cross-serotype–reactive antibody response is thought to wane to 
subneutralizing levels, where antibodies still bind, but do not neutralize the infect-
ing virion. In turn, these antibodies contribute to enhanced infection of Fc receptors 
(FcRs) bearing cells during heterologous DENV encounters (Figure 1)[71, 72]. This 
phenomenon called “antibody dependent enhancement” or ADE, potentially increases 
the risk of developing severe disease by virtue of increasing the number of virus 
infected cells and therefore the viral biomass in vivo accompanied by hyperactiva-
tion of infected-immune cells and increased release of vasoactive mediators that 
resembles some pathologic features of what occurs in patients suffering severe den-
gue disease including capillary permeability and vascular leak (Figure 1)[73–78].
Multiple prospective cohort studies in Asia and Latin America have identified sec-
ondary infection as an epidemiological risk factor for severe dengue [17, 28, 79, 80]. 
Classical epidemiologic and observational studies have suggested that pre-existing 
sub-neutralizing antibodies in closely association with immunologic markers and 
clinical events supports the hypothesis of ADE and the risk of severe dengue dur-
ing secondary infections [16, 26, 27, 78, 81–83]. Maternally derived subneutralizing 
levels of DENV-reactive IgGs have been also postulated to be a critical risk factor for 
severe dengue during infancy [26, 27, 84–86]. Numerous studies performed in animal 
models have reiterated that ADE results in higher viral load in patients at specific 
concentration of antibodies (a peak of enhancement), especially at early stages of 
infection, thereby increasing the risk of developing DHF/DSS [14, 87]. Studies 
performed in rhesus monkeys confirmed that passive transfer of immune serum or 
monoclonal antibodies resulted in increased viremia; however, no apparent signs of 
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severe disease was observed, indicating that severe dengue manifestations may not 
only be a main consequence of increased viremia [65, 88].
Despite all these evidences, yet no conclusive evidence exist that a risk of 
severe dengue disease and ADE occur in humans. A recent study using samples 
from a well-characterized DENV cohort study in children showed that the risk 
of developing severe dengue disease during secondary dengue infections existed 
within a narrow range of preexisting anti-DENV antibody titers, a peak of enhance-
ment, detected in humans [29]. Recently, a phase 3 clinical trial of the only dengue 
vaccine licensed, Dengvaxia [89] showed an increased risk of hospitalization for 
severe dengue in children not exposed to DENV before vaccination [90], raising 
concerns about the need to assess dengue vaccine safety at the earliest development 
stages prior to human vaccination, and confirming that vaccination of DENV-naïve 
individuals may induce poorly neutralizing anti-DENV antibodies that increase 
the risk of severe dengue disease [91]. All these observations indicate that ADE 
may occur in humans and should be an obligate consideration for future designing, 
implementation, and evaluation of vaccine trials, especially those in the flavivi-
rus field.
DENV-ADE can be mediated by E protein-specific antibodies either at low 
antibody concentrations or low antibody avidity, when the number of antibody 
molecules bound per virion is below the threshold necessary for neutralization of 
the virus (a peak of enhancement) [92]. As DENV E protein binds to cellular recep-
tors and mediates viral fusion during entry, it is thought to be the major target of 
neutralizing antibodies [33, 41, 93]. However, a substantial proportion of antibod-
ies generated in response to natural DENV infection are directed toward the pre-M 
protein which represents an important part of the adaptive immune response in 
DENV infected patients [40, 94].
During DENV infection, the cleavage of pre-M protein represents a critical 
step for the virus maturation process [49, 95, 96]. As the cleavage of pre-M is not 
complete in all dengue virions, a proportion of secreted viral particles from infected 
cells are partially mature dengue virions that contain a varying amount of cleaved 
and uncleaved pre-M proteins [42, 96, 97]. Immature dengue viral particles con-
tains regular trimeric E-pre-M protein complexes and are noninfectious [49, 98]. In 
contrast, some partially mature forms, containing some pre-M protein–E protein 
trimers, are partially infectious. In both cases, uncleaved pre-M protein on imma-
ture or partially mature virions can be targeted by the host anti-pre-M antibody 
response which despite being highly cross-reactive among all four DENV serotypes, 
can rarely neutralize virus infection even at high concentrations, but promote ADE 
(Figure 1) [48, 75, 76, 98, 99].
Historically, the DENV-ADE phenomenon has been recapitulated by numerous in 
vitro studies where FcR-bearing immunes cells including human monocyte/macro-
phages-like cell lines [48, 73, 74, 77, 98–103], human pre-basophil-like and immature 
mast cell-like cells [104, 105], human primary derived-monocytes/macrophages, 
dendritic cells, mast cells [75, 76, 106–110], and human derived-PBMCs [111, 112] 
have been infected with distinct DENV serotype strains in the presence of monoclonal 
antibodies or human derived-serum/plasma obtained from DENV infected cases 
[59, 72, 75, 76, 104, 105, 113–115]. Controversially, DENV-ADE for other considered 
immune cells such as endothelial cells [116, 117] have been also described in vitro and 
in vivo [118–121]. However, histochemistry of autopsy samples from fatal dengue cases 
and in vitro assays using peripheral blood cells revealed that macrophages/monocytes 
are primary targets for DENV infection and not endothelial cells [122–127].
In vitro, the increased infection of these target cells results in augmented 
expression/production of cytokines and vasoactive mediators and their release into 
the extracellular milieu where provoke an exacerbated activation of neighboring 
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immune cells and endothelial cells which leads to another critical phenomenon that 
may frequently occur during severe dengue infections known as the “cytokine storm” 
[10, 11, 73, 107, 128–130]. This phenomenon has been described for several other 
virus infections (such as influenza viruses, hantaviruses, and potentially corona-
viruses), where the scenario envisioned is that this excessive immune activation 
creates a cascade of cytokine production or “cytokine storm” resulting in increased 
vascular permeability [131–134]. In vivo, experimental DENV infection in AG129 
[135], showed that sub-neutralizing concentrations of anti-E or anti-pre-M anti-
bodies increased DENV pathogenesis and mortality in mice mainly associated with 
increased circulation of pro-inflammatory cytokines and increased vascular leakage 
[40, 48, 87, 118, 136].
Mechanistically, it is thought that ADE-DENV infection of Fc receptor-bearing 
cells, particularly through the Fc-gamma-receptor IIA (FcγRIIA or CD32) [75, 102, 
137, 138], not only results in a large virus-infected cell mass, rather the activation of 
intracellular signaling pathways [109, 139–142] which leads to the increased secre-
tion of vasoactive immune products by infected cells, such as TNF-α, a cytokine 
produced by activated monocytes, which in elevated levels has been found in serum 
of DHF/DSS patients [71, 86, 143–145]. In addition to TNF- α, an important number 
of immune modulators have been described to be implicated in DENV pathogen-
esis acting upon a complicated network of events to provoke the severe dengue 
outcomes mainly related to increased vascular leakage. In DENV-infected primary 
monocytes or monocytic cell lines, the production of IL-6, IL-8, and interferon 
gamma-induced protein 10 (IP-10), IL-12p70, IL-1β, IL-10 and the prostaglandin 
E2 (PGE2) have been found upregulated [73, 74, 76, 77, 109, 112, 137, 142, 146]. In 
DENV-infected dendritic cells, the production of inflammatory cytokines TNF-α, 
IFN-α, IL-6, IL-10; the chemokines IFN-γ-inducible chemokines CXCL9, CXCL10, 
and CXCL11, PGE2, and also matrix metalloproteinases (MMPs) such as MMP-2 
and MMP-9 were found increasingly produced [75, 76, 147–149]. On the other hand, 
DENV infection of mast cells has showed to elicit the release of potent vasoactive 
cytokines such as IL-1β and IL-6; chemokines, such as CCL3, CCL4, CCL5 and 
CXCL10, and other mast cell-derived mediators including proteases such as chy-
mase and tryptase, leukotrienes, prostaglandins, histamine, and vascular endothe-
lial growth factor (VEGF) which shows the significant influence of mast cells in 
immunity and pathogenesis during DENV infection [104, 107, 150, 151].
In humans, increased levels of many of these soluble factors including IFN-γ,  
TNF-α, IL-1β, IL-4, IL-6, IL-7, IL-10, IL-13, IL-15, IL-17, IL-18, macrophage 
migration inhibitory factor (MIF), chemokines such as IL-8, CCL2, CCL4, CCL5, 
CXCL10 (IP-10) and the monocyte chemoattractant protein-1 (MCP-1) have been 
reported in patients with DHF when compared to DF [1, 10, 152–154]. Studies show 
that elevated levels of IL-6, IL-10, IFN-γ, MIF, and CCL-4 could be used as poten-
tial biomarkers of severe dengue [155, 156]. Additional biological markers such as 
serum lipids [157, 158], prostaglandins, leukotrienes and thromboxane [151, 159], 
free radical compounds such as reactive oxygen and nitrogen oxide species [160, 
161], MPPs [162–164], and several components of the endothelium in the microvas-
culature such as the vascular cell adhesion molecule 1 (VCAM-1), Angiopoietin-1 
and -2 (Ang-1, −2), endothelial-1, [5, 163, 165–167] or carbohydrates including 
glycosaminoglycans (GAGs) and proteoglycans (e.g. HSPG) [168–171] have been 
suggested to play important roles in the pathogenesis of different viral infections, 
including DENV. Changes in the plasma or urine levels of these molecules have been 
shown to act as potential predictors for clinical outcome between patients with 
different stages of DHF disease severity and predictors of disease severity in animal 
models in vivo [168, 170–174].
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1.3 T cell responses and “the antigenic sin” of DENV infection
During DENV replication cycle, the viral genomic RNA encodes for a single poly-
protein that after being cleaved by cellular and viral proteases yield three structural 
proteins and seven nonstructural proteins [42, 175] (See Figure 1A, Part I). Numerous 
studies have demonstrated that DENV infection leads to potent T cell responses, and 
many DENV-T cell epitopes have been found throughout the DENV polyprotein ex 
vivo using human leukocytes and in vivo using murine models [176–179]. These T cell 
epitopes appear to follow the general principles of T cell epitope immunogenicity, 
as they show similar MHC molecule binding kinetics to those of other immuno-
dominant viral epitopes. Several studies indicate that nonstructural proteins are 
more frequently recognized by CD8+ T cells, while structural proteins are better 
recognized by CD4+ T cells. [180, 181]. However, most of the identified CD8+ and/
or CD4+ T cells epitopes predominantly reside in the nonstructural proteins 3 (NS3) 
suggesting that NS3 protein is immunodominantly recognized by T cell epitopes 
in humans infected with DENV [8, 177, 182–184]. On the other hand, CD8+ and 
CD4+ T cell responses have been also identified, to a lesser extent, against other viral 
proteins such as the viral capsid, Ns1, NS2A/B, NS4A/B, and NS5 proteins [177, 178, 
185, 186]. The recognition pattern of T cell receptors (TCRs) to these proteins 
expressed in the context of MHC differs according to the type of HLA which confers 
either susceptibility or protection to severe dengue infections [187, 188]. HLA class I 
and class II alleles have been shown to be associated with the development of DHF/
DSS in different populations [182, 187, 189–192]. However, some specific HLA 
alleles are found to be more significantly common among patients with dengue fever 
than those undergoing severe dengue manifestations suggesting a protective effect 
of DENV-specific T cells [191]. Overall, the T cell immunodominance of DENV is 
quite complex and widely focused on different epitopes identified across the whole 
virus proteome [177, 183, 192]. Given that around 70% of amino acid identity exist 
between all four DENV serotypes, T cell epitopes are also highly cross-reactive and 
this has been suggested to play important roles in protective immunity not only 
against DENV but also other related flavivirus such as Zika virus (ZIKV) [193–195].
The protective role of T cells in viral infections is well established [196]. Dengue 
virus-specific T cells recognize virus-infected cells and respond with a diverse set of 
effector functions, including proliferation, target cell lysis and the production of a 
range of cytokines [197]. In vivo, CD8+ T cells control viral infection via direct cyto-
toxicity, and production of pro-inflammatory cytokines such as IFN-γ and TNF-α; in 
turn, CD4+ T cells induce enhancement of B and CD8+ T cell responses, production 
of inflammatory and anti-viral cytokines, cytotoxicity, and promotion of memory 
responses to defeat viral infections [178, 179, 198–200]. T cell activity requires the 
presentation of viral peptides on the surface of infected cells in the context of MHC 
molecules and, unlike B cells, T cells do not recognize intact virions [196]. In vitro, 
DENV specific CD8+ memory T-cells can lyse MHC-matched virus-infected cells as 
an antiviral mechanism leading to protection [199, 201]. Activation of cytotoxic CD8+ 
T cells after presentation of viral peptides by infected antigen presenting cells (APCs) 
can generate immediate effector functions by expressing cytotoxic molecules such as 
granzyme B and perforin to kill virus-infected cells via MHC I- and MHC II-dependent 
mechanisms [10]. In vivo studies have shown that adoptive transfer of DENV-specific 
CD8+ T cell can partially protect mice from lethal challenge with DENV [202]. Other 
studies involving immunization with antigens that induce DENV-specific T cells but 
not neutralizing antibodies, have also shown that T cells are enough to protect mice 
from lethal infection [179, 203, 204]. These studies suggest that CD4+ or CD8+ T cells 
may have beneficial roles in controlling virus replication during DENV infections.
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Although T cells have important functions in combating viral pathogens, both 
pathological and protective effects of T cells have been reported in the context of 
DENV infection [177, 178]. The association of severe dengue symptoms with a rapid 
decline in viral loads and a peak of pro-inflammatory cytokine secretion have led 
to the proposal of a role for a T cell mediated immune response in driving immuno-
pathology in severe dengue [205]. T cell responses after primary DENV infections 
are characterized by higher homotypic than heterotypic responses [194]. However, 
in secondary DENV infections, T cell responses are highly serotype cross-reactive 
[206] with higher responses maintained to the previously encountered DENV sero-
type [207]. This alteration in the T cell immune responses, skewed by the ‘memory’ 
of the previous infection, is referred to as ‘original antigenic sin” [10, 207] (Figure 1). 
According to this hypothesis, secondary DENV infection is dominated by the expan-
sion of pre-existing nonprotective, cross-reactive and low affinity T cells to the 
new infecting serotype that results in ineffective viral control and elicit an aberrant 
immune response that contribute to immunopathology and severe dengue disease 
through an excessive production of inflammatory cytokines [10, 177, 178, 205, 
207, 208]. Distinct studies in vitro using tetramers containing peptides from either 
the primary or secondary infecting viruses, have provided evidences for the original 
antigenic sin occurring in secondary T cell responses to DENV [207, 209].
The magnitude of the T cell response positively correlates with disease sever-
ity [183, 207]. Studies of the function of dengue-specific T cells has revealed an 
interesting difference between mild and severe infections [183]. Profound activa-
tion of naïve T cells into effector T cells and increased cytokine production have 
been reported in patients with DHF during both primary and secondary DENV 
infections [1]. T cell responses in severe dengue patients mainly produce IFN-γ and 
TNF-α [183]. Additionally, a broad spectrum of cytokines has been shown to be 
produced by DENV-specific T cells in responses to the recognition of peptide–MHC 
complexes on target cells. This array of cytokines follows a T helper 1 (TH1)- or 
TH0-like profile including the production of IFN-γ, TNF-α, IL-2, and MIP1β, also 
known as CCL4, and less commonly, the TH2-type cytokines, IL-4 [15, 193]. Many 
of these T cell-derived cytokines have pleiotropic effects, including the induction or 
enhancement of inflammation and the alteration of vascular permeability that may 
contribute to the systemic disturbances leading to DHF [1, 10, 208].
Despite all this evidence, the relative contribution of DENV activated T cells 
in dengue pathogenesis and control of viral infection is still controversial. Severe 
dengue can occur during a primary dengue infection in which cross-reactive T cells 
and original antigenic sin would not be operative [210]. In addition, the relatively 
low numbers of circulating T cells seen during acute DENV infection and the tem-
poral mismatch between the appearance of DENV NS3-specific CD8+ T cells, and 
the appearance of vascular leakage manifestations, suggests that other mechanisms 
independent of CD8+ T cells are responsible for early triggering of capillary leakage 
in children with DHF [207, 211]. A recent study found that numbers of DENV-
specific T cells were augmented in the skin of DENV-infected patients compared to 
those circulating in the peripheral blood, suggesting that during the acute phase, 
DENV-specific T cells may migrate to the skin and return the bloodstream upon 
viral clearance [212, 213]. During secondary infections, the expansion of the low-
avidity T cells specific for the primary DENV infection may delay viral clearance and 
thereby lead to higher viral loads. These results may explain the asynchronies timing 
between T cells circulating in the blood and the beginning of capillary permeability 
that occurs in DENV infection. However, in the absence of a good animal model of 
disease, it remains controversial whether the expansion of low-avidity cross-reactive 
T cells in secondary dengue infection contributes to disease pathogenesis. In sum-
mary, during DENV infection, the generation of an early T cell response may be 
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protective, whereas the late generation of T cell populations that have a proportion 
of low-avidity T cells and are skewed to inflammatory cytokine production in the 
absence of degranulation may predispose to immunopathology in the presence of 
high viral antigen loads that contributes to the cytokine storm and vascular leak.
1.4 DENV infection, NS1 pathogenesis, and vascular leak
The hallmark and critical feature of severe dengue disease is the increased capil-
lary permeability, causing plasma leakage, which can lead to hemodynamic com-
promise and dengue shock syndrome (DSS) [2–4]. The plasma leakage syndrome, 
is defined as the extensive extravasation and accumulation of fluids out of blood 
vessels into the surrounding tissues and serous cavities, causing serositis which 
includes pleural effusion, and pericardial and peritoneal ascites, leading to hemo-
concentration, hypotension, organ disfunction, and life-threatening shock [6, 214]. 
In DENV infection, the transient nature of plasma leakage, its association with the 
late febrile phase and the paucity of structural damage to the vasculature identi-
fied by autopsy studies initially suggested that circulating factors were primarily 
responsible for this phenomenon [5, 125, 126, 205].
Although a major risk factor for developing severe dengue disease is related 
to the DENV-ADE phenomenon that correlates with increased plasma levels of 
pro-inflammatory cytokines found in the acute phase of patients undergoing severe 
dengue manifestations [1, 83], ADE alone seems not to be sufficient to explain the 
vascular pathology associated with DHF since not all secondary heterotypic infec-
tions results in severe disease, and many individuals also experience DHF during 
primary infection [16]. The association of severe dengue symptoms with a rapid 
decline in viral loads and a peak of pro-inflammatory cytokine secretion suggests 
that although subneutralizing antibodies can increase dengue disease severity via 
ADE, other factors may also influence disease outcome, driving the immunopathol-
ogy in severe dengue [10, 205].
Very recently, a new piece in DENV pathogenesis puzzle, known as the nonstruc-
tural protein 1 or NS1, was reported to directly be involved in inducing endothelial 
dysfunction in vitro and vascular leakage in vivo via alteration of the endothelial 
barrier function and activation of immune cells and platelets, the latter resulting in 
induction of pro-inflammatory signaling pathways leading to increased secretion 
of vasoactive molecules and vascular leakage [9, 215, 216]. Initially recognized as a 
soluble complement-fixing (SCF) antigen detected in the blood of DENV-infected 
patients [217], NS1 of the flavivirus genus including DENV, is the only flaviviral 
protein described to be secreted by infected mammalian and insect cells [218–221], 
which circulates in the bloodstream of DENV-infected patients for up to 14 days 
since the onset of symptoms [222]. This bioavailability feature of NS1 launched it as 
a diagnostic marker for acute primary and secondary DENV infections and poten-
tially other flavivirus diseases [54, 223–225]. NS1 antigenemia can reach as high as 
50 μg/mL during the acute phase of dengue illness correlating with the development 
of DHF and sometimes fatality cases [12, 14, 54, 170, 223, 226–228]. These observa-
tions suggest that circulating levels of NS1 in the bloodstream of patients during the 
clinical phase of the disease may contribute to DENV pathogenesis.
In infected cells, NS1 is found as a membrane-associated dimer in both cellular 
compartments and on the cell surface. NS1 is intracellularly generated as a mono-
meric glycoprotein in the ER of DENV infected cells, where it has been demon-
strated to play essential roles as cofactor in virus replication and virus assembly by 
recruiting cellular proteins as well as viral proteins such as the envelope protein dur-
ing virus morphogenesis which results in the biogenesis of the membranous DENV 
RC organelle [229–233]. NS1 is also secreted by infected cells and recent structural 
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analyses showed that secreted NS1 circulates as a soluble hexamer glycoprotein 
with an atypical open barrel-shape that contains a prominent central lipid-enriched 
core of triglycerides, cholesteryl esters, and phospholipids that evocates a plasma 
high-density lipoprotein [53, 234] (Figure 1). Elucidation of the crystal structures 
of the NS1 hexamers reveal an amphipathic molecule with a hydrophobic inner 
face and a hydrophilic outer face containing three structural domains known as the 
hydrophobic “β-roll”, the “wing” domain, and the c-terminal “β-ladder” domain 
that likely have distinct roles in membrane association, replication complex assem-
bly, and interactions with the immune system and are the basis for elucidating the 
molecular mechanism of NS1 function [235, 236] (See Figure 1B, Part I). These 
same structural domains were also identified by cryo-EM reconstruction studies 
of other related flavivirus NS1 proteins such as West Nile virus (WNV), Zika virus 
(ZIKV), and yellow fever virus (YFV) [237–239].
In addition to the role played in viral replication, NS1 participates in dengue 
immunopathogenesis by inhibiting platelet aggregation and prothrombin activation, 
directing complement against endothelial cells, inducing endothelial cell apoptosis, 
and facilitating the evasion of DENV particles from complement system–dependent 
neutralization [229, 240]. Regarding the complement pathways, NS1 mediates 
complement inactivation through multiple interactions with the complement 
proteins including factor H, C1s and C4, and the C4 binding protein [241–244]. 
These interactions result in attenuation of complement classical, lectin, and alterna-
tive pathways suggesting that extracellular NS1 protein may function to minimize 
immune system responses by decreasing complement recognition of DENV infected 
cells [19]. However, in flavivirus infections, the complement system has been 
described to play an important role in protecting the host but also influencing disease 
pathogenesis [19]. In DENV infected patients with DSS, accelerated complement 
consumption and a marked reduction in plasma complement components has been 
observed, which led to the proposal that complement activation plays an important 
role in disease pathogenesis [20, 245]. Recent studies from human autopsies have 
identified more evidences of increased deposition of complement components from 
both classical and alternative pathways associated with increased liver damage [126].
In the context of DENV NS1, both soluble NS1 and cell membrane-associated 
NS1 have been identified to triggers complement activation and anaphylatoxin 
formation in the presence of polyclonal or monoclonal anti-NS1 antibodies [246] 
(Figure 1). In vitro and in vivo experiments using anti-NS1 specific antibodies as 
well as antiserum obtained from DENV immunized mice and rabbits have reported 
their cross-reactivity with various epitopes found on human plasma proteins 
involved in coagulation pathways such as fibrinogen, plasminogen, and thrombin 
as well as integrin/adhesion proteins, endothelial cells and platelets leading to 
inflammation, apoptosis, and dysfunction of endothelial cells and platelets which 
sometimes results in bleeding issues [247–252]. Based on these evidences, autoim-
mune mechanisms mediated by anti-NS1 antibodies have been also proposed to 
lead to symptoms of DHF related to increasing vascular permeability maybe in 
a complement dependent manner. However, numerous past and new growing 
evidence describing the role of anti-NS1 antibody responses in NS1-immunized 
mouse models, DENV infected patients or DENV vaccine trails suggest an impor-
tant protective effect of anti-NS1 immune responses as prophylactic or therapeutic 
options against DENV infection and other related flavivirus infections [9, 57, 62, 63, 
70, 186, 253–260]. Therefore, the dual role of anti-NS1 antibodies in protection and 
disease still represents a critical challenge that needs to be overcome to develop an 
effective and safe NS1-based vaccine against flavivirus infections.
As mentioned previously, endothelial barrier dysfunction leading to vas-
cular leakage and shock are the major causes of death in patients with dengue 
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hemorrhagic fever (DHF) and dengue shock syndrome (DSS) [2]. The vascular 
alterations observed in dengue cases have been described to be a consequence of 
the imbalance of the host immune system, specially cytokine storm, cytotoxic T 
cell and complement activations [1, 10, 11], in addition to endothelium injuries 
caused by the direct infection of the virus of endothelial cells, as reported by several 
in vitro studies [261, 262]. Endothelial cells, lining the inner side of blood vessels, 
constitute a critical component of the vascular endothelium which are in direct 
contact with the plasma proteins and all cellular components circulating in the 
bloodstream [263]. Under homeostatic conditions, this layer of endothelial cells 
crucially conducts several essential processes such as maintenance of vessel integ-
rity, supply of oxygen and nutrients to underlying tissues and patrolling immune 
cell trafficking [264, 265]. Thus, alterations on its integrity under pathologic 
circumstances result in malfunction which contributes to inflammation and disease 
[265] (Figure 1).
Secreted hexameric DENV NS1 protein has been described to attaches to the 
surface of uninfected cells, primarily human endothelial cells in vitro and in vivo 
via interactions with heparan sulfate and chondroitin sulfate E [266]. In 2015, a 
new role for soluble NS1 in eliciting direct pathogenic effects in DENV disease was 
described [9]. In this study, the barrier function of human pulmonary microvas-
cular endothelial cells (HPMEC) cultured under polarized conditions on semiper-
meable membrane filters (e.g. Transwells inserts) was compromised after being 
exposed to physiological concentrations (0.5–5 ug/mL) of recombinant soluble 
and hexameric NS1 proteins from all four DENV serotypes (DENV 1–4) in vitro. 
Interestingly, this pathogenic effect was recapitulated in vivo when inoculation of 
mice (e.g. Ifnar−/−) with only DENV NS1 in the absence of DENV infection results 
in increased mice morbidity. More interesting, a combination of DENV NS1 with 
a sublethal dose of DENV2 made mice succumbed. These NS1-induced morbidity/
mortality effects in vivo was significantly related to the increased vascular leak 
observed in these mice, phenomenon that was shown to be prevented by NS1 immu-
nization or prophylactic treatment of mice using NS1-derived mouse antiserum or 
anti-NS1 monoclonal antibodies that also blocked NS1-increased permeability of 
HPMEC cultures in vitro. This study demonstrate how NS1 alone was able to medi-
ate DENV pathogenesis by triggering endothelial dysfunction in vitro which was 
linked to increased vascular leak and mortality in vivo [9]. Interestingly, an addi-
tional study showed that the secreted form of NS1 may act as a pathogen associated-
molecular pattern (PAMP) as purified NS1 protein was able to directly activate 
mouse macrophages and human PBMCs via Toll-like receptor 4 (TLR4), which leads 
to the induction and release of pro-inflammatory cytokines and chemokines in vitro 
(e.g. TNF-α, IL-6, IFN-β, IL-1β, and IL-12); later, this effect was prevented by TLR4 
antagonists and anti-TLR4 antibody treatment in a mouse model of DENV infec-
tion [215]. These evidences strongly support the important contribution of NS1 in 
modulating the endothelial cell biology and the inflammatory responses of immune 
cells as two of the main mechanisms described to influence DENV pathogenesis and 
therefore severe disease.
On the endothelium, two main structures work together to maintain the homeo-
stasis of the microvasculature: a network of glycosaminoglycans, glycoproteins, 
and proteoglycans known as the endothelial glycocalyx layer (EGL) and an array 
of protein-to-protein interactions that integrates the intercellular junction complex 
(IJC), mainly composed by tight and adherens junction proteins, and other struc-
tures such as gaps and desmosomes [257–259]. Based on the first set of evidence 
showing a direct role of NS1 on the endothelial cell barrier, subsequent studies 
have identified distinct mechanisms triggered by DENV NS1 to cause endothelial 
hyperpermeability and vascular leak such as disruption of EGL (e.g. sialic acid, 
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heparan sulfate, syndecan-1) expressed on the surface of HPMEC and the micro-
vasculature in vivo via activation/expression of endothelial enzymes including 
sialidases, heparanase, and cathepsin L, a lysosomal cysteine proteinase, all of these 
occurring in a cytokine-independent manner [267, 268] (Figure 1). An additional 
study corroborates these findings showing that NS1 induces the increased secretion 
of vasoactive molecules such as the macrophage migration inhibitory factor (MIF) 
and the angiopoietin-1 and 2 (Ang-1/Ang-2) from human endothelial cells (e.g. 
HMEC-1 from dermis) and DENV infected patients. These molecules were shown 
to activate autophagy pathways, phosphorylation cascades, and actin cytoskeleton 
rearrangements leading to disarrangement and internalization of VE-cadherin, an 
adherens junction protein of endothelial cell-to-cell contacts, inflammation, and 
also secretion of heparanase, shedding of sydencan-1 (CD138), and expression of 
MMP-9 from immune cells, resulting in degradation of EGL and hyperpermeability 
in vitro [269–272]. Follow up studies in human primary monocytes, monocytic cell 
lines, and human platelets stimulated with exogenous NS1 in vitro have additionally 
demonstrated the NS1-mediated activation and stimulation of pro-inflammatory 
cytokines and proteases (e.g. MMPs) via TLR4 signaling supporting previous 
reports of NS1 protein acting as a PAMP leading to inflammation, thrombocytope-
nia, hemorrhage and disease in DENV infection [273–275].
Besides DENV, the flavivirus genus includes other human medically important 
mosquito-borne pathogens such as ZIKV, WNV, Japanese encephalitis virus (JEV), 
and YFV [276]. In humans, flaviviruses can cause a wide spectrum of systemic or 
neurotropic-encephalitic pathologies ranging from clinically inapparent infections 
to severe, sometimes fatal disease, characterized by hemorrhagic manifestations 
and vascular leakage with organ failure (DENV and YFV), encephalitic manifesta-
tions (JEV and WNV), and congenital Zika syndrome in pregnancy and Guillain-
Barré syndrome in adults associated with ZIKV infection [277, 278]. In recent 
studies, NS1 proteins from other DENV-closely related flavivirus including ZIKV, 
WNV, JEV, and YFV also demonstrated to cause endothelial hyperpermeability 
and vascular leak [172, 173, 279]. Interestingly, NS1 proteins selectively bind to and 
alters permeability of human endothelial cells from distinct tissues including lung, 
dermis, umbilical vein, brain, and liver in vitro and causes tissue-specific vascular 
leakage in mice, reflecting the pathophysiology of each flavivirus. Mechanistically, 
flaviviruses NS1 trigger the disruption of EGL components to cause endothelial 
hyperpermeability [172, 173, 253, 279]. On the vascular endothelium, the EGL 
constitutes a network of GAGs such as heparan sulfate, chondroitin sulfate, and 
hyaluronic acid, and proteoglycans (e.g., syndecans, glypicans, and perlecan) 
that contributes to maintain the homeostasis of the endothelial barrier function 
[280]. Degradation of the EGL and the detection of its degradation products in cell 
supernatants and human plasma have been linked to virus pathogenesis and disease 
severity in several viral hemorrhagic fever diseases [281], including dengue, where 
increased levels of heparan sulfate, hyaluronic acid, sialic acid, and syndecan-1 
have been found to correlate with severe dengue disease in humans and lethality in 
animal models [3, 168–170, 172].
This NS1 pathogenic effect on the endothelium requires the internalization 
of the soluble NS1 protein inside human endothelial cells [279] (Figure 1). This 
process occurs via clathrin-mediated endocytosis and relies on one of the glyco-
sylation sites (Asparigine-207) located in the Wing domain of NS1 [279]. DENV 
NS1 contains two conserved N-linked glycans at the asparagine-130 (N130) and 
the asparagine-207 (N207) which have been implicated in NS1 hexamer secretion, 
stability, and function [234, 236, 282, 283]. Previous studies investigating the 
importance of the N-glycans on NS1 have found that deglycosylated flaviviral NS1 
proteins at either site, exhibited significant attenuation of neurovirulence in mice 
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compared to the wild-type virus [284–286]. Additional in vitro studies have shown 
that endocytosis of DENV NS1 occur in human hepatocytes which may potentialize 
subsequent DENV infection [221].
Flavivirus infection has been shown to compromise the integrity of many 
biological barriers, including the lung microvascular endothelium and the blood–
brain barrier, which are usually able to protect against virus infection [287, 288]. 
Numerous studies of flavivirus infection in different animal models as well as human 
autopsies have shown a selective tropism of distinct groups of flaviviruses that target 
different tissues, leading to systemic versus neurotropic-encephalitic pathology 
[277]. The fact that NS1 internalization is required to induce endothelial hyperper-
meability and increased vascular leak through a flaviviral-conserved endothelial 
cell-intrinsic pathways, and the finding that the flaviviral virulence depends on the 
expression of N-glycans on soluble NS1, suggest the possibility that NS1 may favor 
virus propagation and pathogenesis in vivo. During the acute phase of DENV infec-
tion high NS1 antigenemia have been correlated with increased risk of developing 
severe dengue disease, including vascular leakage [12, 14]; however, little is known 
about circulating levels of NS1 from other flavivirus infections. Future studies 
intended to investigate the kinetics and dynamics of NS1 circulation in flavivirus-
infected patients different than DENV, will help to better understand the role of NS1 
in flavivirus pathogenesis and disease. NS1 is well conserved among flaviviruses 
(20–40% identity, 60–80% similarity) [289], therefore, these findings reveal the 
capacity of a secreted viral protein from related flaviviruses named as NS1 flaviviral 
toxin as critical for pan-flavivirus pathogenesis through modulation of the endo-
thelial barrier function in a tissue-specific manner, potentially influencing virus 
dissemination and pathogenesis of target organs and representing a novel target for 
anti-flaviviral therapy and potential vaccine candidates against flavivirus infections.
2. Concluding remarks (PART II)
Systemic vascular leakage associated with DENV infection is the most serious 
complication and the most important contributor to severe clinical outcomes during 
severe dengue disease that result in life-threatening complications such as hypo-
tension, organ failure, and shock. Epidemiological data strongly associate severe 
dengue disease with secondary heterotypic DENV infections occurring in the pres-
ence of pre-existing antibody responses, widely attributed to the phenomenon of 
antibody-dependent enhancement (ADE). Numerous studies in vivo and in vitro have 
tightened DENV-ADE to the increased activation of immune cells such as mono-
cytes, macrophages, dendritic cells, and mast cells leading to the generation of the 
pro-inflammatory environment found in many patients undergoing severe dengue, 
known as “cytokine storm”. Along with DENV-ADE, heterotypic immunity originated 
during primary DENV infection may also lead to alterations in immune responses 
of T cells, skewed by the ‘memory’ of the previous infection, referred to as ‘original 
antigenic sin’. These DENV cross-reactive T cell responses produce only inflamma-
tory cytokines and might be inherently inefficient in killing DENV-infected cells, 
resulting in enhanced infection, which may predispose to the immunopathology of 
DENV.
Along with this evidence, in the last decades, several other immunologic mecha-
nisms such as activation of complement pathways and autoimmune responses (e.g. 
mimetic anti-DENV antibodies) have been also linked to ensure severe dengue 
manifestations leading to the activation and apoptosis of immune cells and endo-
thelial cells, aggregation of platelets, and inactivation of plasma proteins involved 
in coagulation cascades. On the other hand, viral biomarkers such as NS1, which 
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high circulating levels correlated with the appearance of severe dengue disease, 
was reported to modulate complement pathways, facilitating virus infection via 
immune evasion strategies. NS1 has demonstrated to exert an amazing array of 
different functions. More recently, NS1 was demonstrated to be a multitasking 
protein of the flavivirus genus which could directly cause disruption of the EGL and 
endothelial cell-to-cell contacts, two main components of the homeostasis balance 
in the microvasculature, and to induce the production of soluble immunoregulators 
resulting in increased endothelial barrier dysfunction and vascular leakage. This 
evidence provides new insights into the biology of the multifaceted NS1 protein 
of flavivirus that may improve the understanding of the flavivirus pathogenesis, 
strongly supporting the inclusion of NS1 protein in flavivirus vaccine development 
and the generation of new targets for future therapies against flavivirus infections.
In conclusion, the immunopathogenesis of DENV infection represents an 
extraordinarily complex interplay between several viral and host factors that 
together contribute intimately to the activation of distinct immunopathological 
processes that although were intended to control the viral infection and replication, 
instead unleash an unbalanced host immune response leading to increased endothe-
lial dysfunction and vascular leakage, reflected in the appearance of dengue severe 
manifestations. As no effective vaccine or antiviral therapy are available to treat 
either prophylactically or therapeutically the DENV infection, the incidence of den-
gue disease is expanding globally and continues to threat the public health services 
worldwide, particularly in endemic areas. An increased understanding of DENV 
immunopathogenesis mechanisms involved in the development of severe disease, 
their components, biological triggers, and their potential connections will assist not 
only the development of potentially more effective novel therapeutic interventions 
but also the understanding of dengue vaccine efficacy or vaccine adverse events that 
can be considered during vaccine trial interventions.
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